Pfizer says FY26 adj. EPS guidance includes ~$0.10 hit from Innovent charge
Pfizer revised its FY26 guidance, including a $0.10 EPS hit from a $650M Innovent charge and $1.1B revenue impact from competition. It raised adjusted EPS to $2.95-$3.05 and revenue to $62B-$64B, with increased R&D and SI&A expenses. Q3 adjusted EPS beat estimates at $0.87, while revenue slightly declined YoY to $16.583B.
How this was made
The 30-second read
Why it matters
The guidance lift suggests confidence in top‑line growth, but the disclosed charge highlights cost headwinds that could affect margins.
Market read
First report of Pfizer's FY26 guidance revision; material numbers likely to move the stock and influence sector sentiment.
What to watch
Potential downstream impact of the Innovent licensing charge on future R&D spending and pipeline timing.
Background
Pfizer updated its FY26 outlook, adding a $650M licensing charge and revising revenue, R&D, and SI&A expense ranges.
Ticker impact
Pfizer disclosed FY26 adjusted EPS guidance includes a $0.10 hit from a $650M Innovent licensing charge and raised revenue and EPS forecasts.
potential modest upside as the raised EPS guidance may offset the licensing charge
The new guidance is a primary disclosure with material dollar amounts; traders can price in the EPS hit and higher revenue outlook immediately.
Market effects
Pharma sector may see slight re‑rating as Pfizer's guidance adjusts expectations for licensing charges and competitive erosion.
U.S. large‑cap healthcare index could experience modest movement.
Limited to investors tracking major drugmakers and biotech licensing trends.
Counterpoint
The $0.10 EPS hit may signal hidden cost pressures; investors could be cautious despite higher revenue guidance.
Key entities
- companyPfizer
Global pharmaceutical company providing FY26 guidance.
- companyInnovent
Licensor of a product generating a $650M charge to Pfizer.
